ZNF217肿瘤基因在卵巢浆液性囊腺癌20号染色体的表达及其临床意义

目的 探讨ZNF217肿瘤基因（锌指蛋白217）在卵巢浆液性上皮癌20号染色体的表达情况．以及与卵巢癌的分级及预后的关系。方法 应用荧光原位杂交技术及20号染色体特异序列探针（含ZNF217肿瘤基因）对石蜡组织的卵巢浆液性囊腺癌23例（其中I期11例、Ⅲ～Ⅳ期12例）、浆液性囊腺瘤10例、正常卵巢组织7例进行检测。结果 卵巢癌出现ZNF217基因扩增有12例（其中分化晚期卵巢癌9例，早期卵巢癌3例）。占52．17％。卵巢浆液性囊腺瘤有1例出现ZNF217基因扩增，正常卵巢组织未出现基因扩增。ZNF217基因在晚期卵巢癌和早期卵巢癌以及卵巢癌与卵巢良性肿瘤、正常卵巢组织中的拷贝数有显著性差异（P〈0．05）。结论 ZNF217基因与卵巢癌的临床分期、预后不良有关。

Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications

Objective To investigate the amplification of zinc finger protein 217 (ZNF217) gene on chromosome 20 in ovarian cancer and its clinical significance. Methods Twenty-three specimens of ovarian carcinoma (11 cases of early stage and 12 advanced stage), 10 specimens of benign ovarian tumors and 7 normal ovaries were examined for ZNF217 gene amplification on chromosome 20 by fluorescence in situ hybridization (FISH). Results ZNF217 gene amplification was detected in 12 cases of ovarian cancer (52.17%) and 1 case of benign ovarian tumor, but not in normal ovary. ZNF217 amplification was significantly associated with ovarian cancer. Conclusion Oncogene ZNF217 is associated with the tumor stage and poor prognosis of patients with ovarian cancer.